Biology of Blood and Marrow Transplantation
Volume 15, Issue 12 , Pages 1523-1530 , December 2009

Antibody Response to Polysaccharide Conjugate Vaccines after Nonmyeloablative Allogeneic Stem Cell Transplantation

  • Aafke Meerveld-Eggink

      Affiliations

    • Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands
    • ,
  • Ankie M.T. van der Velden

      Affiliations

    • Department of Hematology, Vrije Universiteit (VU) University Medical Center, Amsterdam, The Netherlands
    • ,
  • Gert J. Ossenkoppele

      Affiliations

    • Department of Hematology, Vrije Universiteit (VU) University Medical Center, Amsterdam, The Netherlands
    • ,
  • Arjan A. van de Loosdrecht

      Affiliations

    • Department of Hematology, Vrije Universiteit (VU) University Medical Center, Amsterdam, The Netherlands
    • ,
  • Douwe H. Biesma

      Affiliations

    • Department of Internal Medicine and Hematology, University Medical Center, Utrecht, The Netherlands
    • ,
  • Ger T. Rijkers

      Affiliations

    • Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands
    • Corresponding Author InformationCorrespondence and reprint requests: GT Rijkers, PhD, Department of Medical Microbiology and Immunology, St. Antonius Hospital Nieuwegein, Koekoekslaan 1, PO Box 2500, 3534 CM Nieuwegein, The Netherlands.

Received 7 May 2009 ,Accepted 22 July 2009.

  • Image Result

    (A) Geometric mean titers before and after Hib and pneumococcal vaccination. Geometric mean titers (in μg/mL) with 95% confidence interval prevaccination (gray columns) and postvaccination (black colu

    (A) Geometric mean titers before and after Hib and pneumococcal vaccination. Geometric mean titers (in μg/mL) with 95% confidence interval prevaccination (gray columns) and postvaccination (black columns). (B) Geometric mean titers before and after tetanus vaccination. Geometric mean titers (in IU/mL) with 95% confidence interval prevaccination (gray column) and postvaccination (black column).

  • Image Result
    (A) Percentage of patients with pneumococcal serotype-specific IgG concentrations ≥0.35μg/mL pre- and postvaccination. Percentage of patients with pneumococcal serotype-specific IgG concentrations ≥0.

    (A) Percentage of patients with pneumococcal serotype-specific IgG concentrations ≥0.35μg/mL pre- and postvaccination. Percentage of patients with pneumococcal serotype-specific IgG concentrations ≥0.35μg/mL before (gray columns) and after (black columns) vaccination. (B). Percentage of patients with pneumococcal serotype-specific IgG concentrations ≥1.0μg/mL pre- and postvaccination. Percentage of patients with pneumococcal serotype-specific IgG concentrations ≥1.00μg/mL before (gray columns) and after (black columns) vaccination.

  • Image Result
    Percentage of patients with anti-Hib IgG concentrations ≥1.0 μg/mL pre- and postvaccination. Percentage of patients with anti-Hib IgG concentrations ≥1.0 μg/mL before (gray column) and after (black co

    Percentage of patients with anti-Hib IgG concentrations ≥1.0 μg/mL pre- and postvaccination. Percentage of patients with anti-Hib IgG concentrations ≥1.0 μg/mL before (gray column) and after (black column) vaccination.

  • Image Result
    Percentage of patients with antitetanus toxoid IgG concentrations ≥0.1 IU/mL pre- and postvaccination. Percentage of patients with antitetanus toxoid IgG concentrations ≥0.1 IU/mL before (gray column)

    Percentage of patients with antitetanus toxoid IgG concentrations ≥0.1 IU/mL pre- and postvaccination. Percentage of patients with antitetanus toxoid IgG concentrations ≥0.1 IU/mL before (gray column) and after (black column) vaccination.

 Financial disclosure: See Acknowledgments on page 1529.

PII: S1083-8791(09)00361-9

doi: 10.1016/j.bbmt.2009.07.020

Biology of Blood and Marrow Transplantation
Volume 15, Issue 12 , Pages 1523-1530 , December 2009

Article Tools

* Image Usage & Resolution